Axiogenesis is now an official member of the HESI Cardiac Safety Technical Committee (CSC). The HESI CSC is a consortium of leading pharmaceutical companies and experts focused on collectively advancing the science behind understanding risks of drug-induced cardiac liabilities.
A major initiative being driven by HESI, the US Food & Drug Administration (FDA) and the Safety Pharmacology Society (SPS) is the establishment of a Comprehensive In Vitro Proarrhythmia Assay (CiPA) for early prediction of potential cardiac arrhythmias as a side effect of pharmaceuticals. Axiogenesis will serve on the Myocyte Working Group of the CiPA initiative, applying its nearly 10 years experience in developing and producing stem cell-derived cardiomyocytes for early compound screening.
For the complete release, click here.